The analysis of low-dose glucocorticoid maintenance therapy in patients with primary nephrotic syndrome suffering from COVID-19
Yong-Qi Li, Min Wu, Yu-Jia Wang, Yu-Xia Zhang, Jing Lu, Yi-Nan Zhao, Bo-Fan Ji, Zhi-Qing Chen, Ri-Ning Tang, Bi-Cheng Liu · 2024
Read The analysis of low-dose glucocorticoid maintenance therapy in patients with primary nephrotic syndrome suffering from COVID-19 by Yong-Qi Li, Min Wu, Yu-Jia Wang, Yu-Xia Zhang, Jing Lu, Yi-Nan Zhao, Bo-Fan Ji, Zhi-Qing Chen, Ri-Ning Tang, Bi-Cheng Liu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10808412.txt.
Description
Yong-Qi Li and co-authors studied COVID-19 outcomes in kidney patients who stayed on low steroid doses, in a study the text dates to 2023. The patients had nephrotic syndrome, a kidney condition that leaks protein into urine, and all had reached full or near remission before catching COVID-19. The study covered one hospital's patients from early 2022 to early 2023.
Of one hundred and twenty-five patients, those kept on low-dose steroids reported milder illness: less fatigue, fewer smell and taste problems, and less fever. Their quality-of-life scores were higher, and a blood marker of inflammation ran lower. The comparison group took no steroids. The authors read the pattern as a sign that gentle steroid cover may soften COVID-19 in this group, though the study only looks back at records.
Catalog record
| CREATOR | Yong-Qi Li, Min Wu, Yu-Jia Wang, Yu-Xia Zhang, Jing Lu, Yi-Nan Zhao, Bo-Fan Ji, Zhi-Qing Chen, Ri-Ning Tang, Bi-Cheng Liu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |